J. Brian Copley

834 total citations
26 papers, 616 citations indexed

About

J. Brian Copley is a scholar working on Nephrology, Nutrition and Dietetics and Surgery. According to data from OpenAlex, J. Brian Copley has authored 26 papers receiving a total of 616 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Nephrology, 9 papers in Nutrition and Dietetics and 5 papers in Surgery. Recurrent topics in J. Brian Copley's work include Parathyroid Disorders and Treatments (11 papers), Magnesium in Health and Disease (8 papers) and Dialysis and Renal Disease Management (5 papers). J. Brian Copley is often cited by papers focused on Parathyroid Disorders and Treatments (11 papers), Magnesium in Health and Disease (8 papers) and Dialysis and Renal Disease Management (5 papers). J. Brian Copley collaborates with scholars based in United States, United Kingdom and France. J. Brian Copley's co-authors include Rebecca Sadler, George L. Bakris, Sue E. Leurgans, Amy J. Mangrum, Rosamund Wilson, Peter Preston, Michael W. Keith, Hong Wan, Friedrich C. Luft and Lisa E. Harris and has published in prestigious journals such as Kidney International, Hypertension and Journal of the American Society of Nephrology.

In The Last Decade

J. Brian Copley

25 papers receiving 586 citations

Peers

Countries citing papers authored by J. Brian Copley

Since Specialization

Citations

This map shows the geographic impact of J. Brian Copley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Brian Copley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Brian Copley more than expected).

Fields of papers citing papers by J. Brian Copley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Brian Copley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Brian Copley. The network helps show where J. Brian Copley may publish in the future.

Co-authorship network of co-authors of J. Brian Copley

This figure shows the co-authorship network connecting the top 25 collaborators of J. Brian Copley. A scholar is included among the top collaborators of J. Brian Copley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Brian Copley. J. Brian Copley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Retrospective Study of Clinical and Economic Burden of Focal Segmental Glomerulosclerosis (FSGS) in the United States 2021 ·Kidney International Reports ·Kamyar Kalantar‐Zadeh, Christine L. Baker, J. Brian Copley, David Lévy, Stephen P. Berasi, Nihad Tamimi, José Alvir, Suneel Udani	6
2	PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis 2021 ·Kidney International Reports ·Laurence H. Beck, Stephen P. Berasi, J. Brian Copley, Donal Gorman, David Lévy, Chay Ngee Lim, Joel Henderson, David J. Salant, Lu W	10
3	Sources of Variability in Podocyte Foot Process Width Measurements and Approaches to Mitigation 2020 ·Journal of the American Society of Nephrology ·(unknown), (unknown), Donal Gorman, Hui Chen, Kondala R. Atkuri, Stephen P. Berasi, J. Brian Copley, Joel Henderson	1
4	Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia 2017 ·Drugs in Context ·Rosamund Wilson, J. Brian Copley	2
5	Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial 2014 ·BMC Nephrology ·Pablo Ureña‐Torres, Dominique Prié, (unknown), Peter Preston, (unknown), Hong Wan, J. Brian Copley	27
6	Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients 2014 ·International Journal of Nephrology and Renovascular Disease ·F A Gibson, Kimberly F Farrand, J. Brian Copley, (unknown), Moshe Fridman, Michael W. Keith, Lynne Poole	4
7	Dietary Trends and Management of Hyperphosphatemia Among Patients With Chronic Kidney Disease: An International Survey of Renal Care Professionals 2014 ·Journal of Renal Nutrition ·Denis Fouque, (unknown), Elizabeth Lindley, Susan Rogers, (unknown), (unknown), J. Brian Copley	14
8	Real-World Dose-Relativity, Tablet Burden, and Cost Comparison of Conversion Between Sevelamer Hydrochloride/Carbonate and Lanthanum Carbonate Monotherapies 2014 ·Clinical Therapeutics ·Michael W. Keith, Scott Sibbel, J. Brian Copley, Rosamund Wilson, Steven M. Brunelli	3
9	MANAGEMENT OF HYPERPHOSPHATAEMIA: PRACTICES AND PERSPECTIVES AMONGST THE RENAL CARE COMMUNITY 2014 ·Journal of Renal Care ·Christina Nagel, (unknown), Elizabeth Lindley, Susan Rogers, (unknown), (unknown), J. Brian Copley, Denis Fouque	2
10	Cost-Minimization Analysis of Lanthanum Carbonate Versus Sevelamer Hydrochloride in US Patients With End-stage Renal Disease 2014 ·Clinical Therapeutics ·Michael W. Keith, Rosamund Wilson, Peter Preston, J. Brian Copley	15
11	Dose relativity of sevelamer hydrochloride and lanthanum carbonate under real-world conditions: Implications for management of patients with end-stage renal disease and hyperphosphatemia 2013 ·Value in Health ·J. Brian Copley, Rosamund Wilson, Michael W. Keith	0
12	The Real-World Dose-Relativity of Sevelamer Hydrochloride and Lanthanum Carbonate Monotherapy in Patients with End-Stage Renal Disease 2013 ·Advances in Therapy ·Rosamund Wilson, Michael W. Keith, Peter Preston, J. Brian Copley	11
13	Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients 2013 ·BMC Nephrology ·A. Hutchison, (unknown), J. Brian Copley, Lynne Poole, Rosamund Wilson	15
14	Evaluation of Cinacalcet HCl Treatment After Kidney Transplantation 2010 ·Transplantation Proceedings ·J. Brian Copley, Michael J. Germain, Leonard Stern, O. Pankewycz, S Katznelson, T. Shah, O. Wang, Stewart A. Turner, Stuart M. Sprague	20
15	CARDIOVASCULAR RISK PROFILE OF RENAL TRANSPLANT RECIPIENTS ENROLLED IN AN OPEN LABEL, RANDOMIZED STUDY COMPARING 2 SIROLIMUS (SRL) REGIMENS WITH A TACROLIMUS (TAC) + MYCOPHENOLATE REGIMEN (MMF): PRELIMINARY RESULTS FROM THE ORION TRIAL 2008 ·Transplantation ·(unknown), Stuart M. Flechner, Sandra M. Cockfield, J. M. Grinyó, Karl Martin Wissing, C. Legendre, J. Brian Copley	2
16	Phase I study of oral bioflavonoids in cadaveric renal transplant recipients: effects on delayed graft function and calcineurin inhibitor toxicities 2003 ·Transplantation Proceedings ·Daniel A. Shoskes, (unknown), (unknown), (unknown), J. Brian Copley	5
17	Cyclosporine to Tacrolimus: Effect on Hypertension and Lipid Profiles in Renal Allografts 1998 ·Transplantation Proceedings ·J. Brian Copley, (unknown), Jill S. Lindberg, (unknown), Clifford J. Bailey, Ravinder Anand, Paul Van Veldhuisen	22
18	Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy 1996 ·Kidney International ·George L. Bakris, J. Brian Copley, (unknown), Rebecca Sadler, Sue E. Leurgans	299
19	Effect of Hypertension and Type II Diabetes on Renal Function in an Urban Population 1990 ·American Journal of Hypertension ·William M. Tierney, Lisa E. Harris, J. Brian Copley, Friedrich C. Luft	14
20	Communication of Information About Therapeutic Alternatives: End-Stage Renal Disease Model 1989 ·Southern Medical Journal ·Clark McCauley, John P. Johnson, J. Brian Copley	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact